HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Novartis Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Novartis Intelligence Report

Generated from 48 signals · 9 evidence sources

Type

Company Intelligence Report

Generated

Aug 4, 2026

Confidence

Moderate Confidence · 72%

Evidence

249 items

Sources

64

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Novartis maintains an active intelligence profile across Diabetes, SGLT2 Inhibitor, Oncology, Radiopharmaceutical, Immunology. 48 signals are linked with 1 investigate-priority items requiring leadership attention. Competitive pressure is high with high portfolio impact. Evidence coverage stands at 72% across 9 tracked sources. Highest-priority development: FDA Accepts Supplemental Application for Emgality (Galcanezumab). Portfolio development. FDA Accepts Supplemental Application for Emgality (Galcanezumab) is an owned Novartis portfolio development in Neurology · CGRP Inhibitor.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJun 17, 2026

    Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

    Ophthalmology · Ocular Inflammation · opportunity score 217

    View detail
  2. portfolio

    FDA Accepts Supplemental Application for Emgality (Galcanezumab)

    FDA approval

    View detail
  3. portfolio

    AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA

    FDA approval

    View detail
  4. portfolio

    FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)

    FDA approval

    View detail
  5. portfolio

    FDA Submission Overview for Dapagliflozin by Sciegen Pharmaceuticals

    FDA approval

    View detail
  6. competitive

    Novartis (named in signal competitive context)

    Elevated competitive pressure

    View detail
  7. competitive

    FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)

    Potential competitive pressure

    View detail
  8. regulatory

    Withdrawn | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Verified Clinical Benefit | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 10161 with buyer quality 10 (Enterprise). Competitive pressure: High. Portfolio impact: High. 1 investigate-priority signal warrant near-term portfolio review. Competitiva linkage surfaces 2 competitive findings requiring monitoring.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Novartis (named in signal competitive context)

    Moderate Confidence · 72%

    Elevated competitive pressure

    Source: FDA, Competitiva

    View evidence

  • FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)

    Moderate Confidence · 65%

    Potential competitive pressure

    Source: Humanexa Signals, Competitiva

    View evidence

  • FDA Accepts Supplemental Application for Emgality (Galcanezumab)

    Low Confidence · 0%

    FDA approval

    Source: Humanexa Signals, FDA, Portfolio

    View evidence

  • AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA

    Low Confidence · 0%

    FDA approval

    Source: Novartis, FDA, Portfolio

    View evidence

  • FDA Approves Supplemental Application for INREBIC (Fedratinib Hydrochloride)

    Low Confidence · 0%

    FDA approval

    Source: Humanexa Signals, FDA, Portfolio

    View evidence

  • FDA Submission Overview for Dapagliflozin by Sciegen Pharmaceuticals

    Low Confidence · 0%

    FDA approval

    Source: Humanexa Signals, FDA, Portfolio

    View evidence

  • Withdrawn | Cancer Accelerated Approvals

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Centaur Pharmaceuticals Private Ltd. - 651080 - 12/03/2025

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DAPAGLIFLOZIN (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Priority Review for KISQALI Supplement by Novartis

    Oncology · CDK4/6 Inhibitor

  • FDA Approves Supplemental Application for IBRANCE (Palbociclib)

    Oncology · CDK4/6 Inhibitor

  • FDA Grants Priority Review for Novartis' Fabhalta (Ipacopan Hydrochloride)

    Hematology · Complement Inhibitor

  • Novartis Fabhalta® (iptacopan) gains FDA approval for primary IgAN treatment

    Nephrology · Complement Inhibition

  • FDA Grants Priority Review for KISQALI FEMARA Co-Packaged Product

    Oncology · Combination Therapy

  • Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

    Ophthalmology · Ocular Inflammation

  • FDA Acceptance of Supplement for AFINITOR (Everolimus) by Novartis

    Oncology · mTOR Inhibitor

  • FDA Accepts Supplement for Mekinist (Trametinib) by Novartis

    Oncology · MEK Inhibitor

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.